As part of its commitment to bringing the best of science to patients, Merck
continues to collaborate with companies, institutions, academics and other
organizations around the world. In 2007 alone, Merck developed 55 significant
new partnerships, and has entered into nearly 250 in the past five years.
Below are some examples of announced collaborations from 2005–2007.
Asia
-
Advinus
India
Metabolic Disorders
-
Nicholas Piramal
India
Cancer
-
Shanghai Biochip
China
Cancer
Australia & New Zealand
Europe
-
Addex
Switzerland
Central Nervous System
-
Artemis
Germany
RNAi Technology
-
Crucell
Netherlands
Vaccines
-
Intercell
Austria
Vaccines
-
Morphosys
Germany
Antibodies
Europe
-
Nicox
France
Cardiovascular
-
Prosidion
United Kingdom
Diabetes
Middle East
-
Compugen
Israel
Chemistry
North America
-
Acumen
United States
Alzheimer’s disease
-
Agensys
United States
Cancer
-
Ambrilia
Canada
Antivirals
-
Ambrx
United States
Diabetes
-
Ariad
United States
Cancer
-
Asuragen
United States
Cancer
-
Avalon
United States
Cancer
North America
-
Aveo
United States
Cancer
-
Celera Diagnostics
United States
Cancer
-
Coley
United States
Vaccines
-
Cubist
United States
Antibacterial
-
Dynavax
United States
Vaccines
-
EV3
United States
Cardiovascular
-
Geron
United States
Cancer
-
GTX
United States
Endocrine
-
Harvard University
United States
Ophthalmology
-
Idera
United States
Vaccines
-
J. David Gladstone Institutes
United States
Alzheimer’s Disease
-
Kinemed
United States
Cardiovascular
North America
-
Melior Discovery
United States
Central Nervous System
-
Metabasis
United States
Diabetes
-
Moffitt Cancer Center
United States
Cancer
-
Monogram
United States
Antiviral
-
Neuromed
Canada
Pain
-
Novacardia
United States
Cardiovascular
-
Paratek
United States
Antibiotics
-
PDL
United States
Antibodies
-
Protiva
Canada
siRNA
-
Surmodics
United States
Ophthalmology
-
Znomics
United States
Metabolic
|
